Get the Stockscreener App
0.6116
2.18%
-0.0136
Pavmed Inc stock is traded at $0.6116, with a volume of 202.62K.
It is down -2.18% in the last 24 hours and down -5.76% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$0.6252
Open:
$0.62
24h Volume:
202.62K
Relative Volume:
1.23
Market Cap:
$11.47M
Revenue:
$4.03M
Net Income/Loss:
$24.32M
P/E Ratio:
-0.1422
EPS:
-4.3008
Net Cash Flow:
$-45.76M
1W Performance:
-7.77%
1M Performance:
-5.76%
6M Performance:
-10.06%
1Y Performance:
-39.45%
1-Day Range:
$0.5864
$0.63
1-Week Range:
$0.5864
$0.69
52-Week Range:
$0.55
$1.90
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.6116 | 11.47M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
|
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
86.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.27 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
PAVmed (NASDAQ:PAVM) Given New $19.00 Price Target at Ascendiant Capital Markets - Defense World
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know - MSN
PAVM: Ascendiant Capital Maintains Buy Rating but Lowers Price Target | PAVM Stock News - GuruFocus
PAVmed subsidiary Veris Health partners with Ohio State University cancer center - Yahoo Finance
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnersh - GuruFocus
PAVM Subsidiary Veris Health Partners with OSUCCC -- James for Cancer Care Innovations | PAVM Stock News - GuruFocus
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer CenterJames Cancer Hospital and Solove Research Institute | PAVM Sto - GuruFocus
Major Cancer Center Adopts PAVmed's Digital Health Platform After Successful Pilot Program - Stock Titan
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com UK
Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool - Stock Titan
PAVmed Inc. (NASDAQ:PAVM) Q1 2025 Earnings Call Transcript - Insider Monkey
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification - Yahoo Finance
Pavmed Inc. Reports Turnaround with Strong Q1 Earnings - TipRanks
PAVmed Q1 2025 slides: net income soars amid strategic restructuring By Investing.com - Investing.com India
PAVmed Q1 2025 slides: net income soars amid strategic restructuring - Investing.com
Earnings call transcript: PAVmed’s Q1 2025 sees strong net income and strategic shifts - Investing.com Nigeria
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Reports Q1 2025 Financial Results and Updates - TipRanks
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results | PAVM Stock News - GuruFocus
PAVmed Q1 Earnings: $40M Cash Runway Powers Multi-Subsidiary Growth and Biopharma Entry Plans - Stock Titan
PAVmed (PAVM) Q1 Earnings Beat with Improved EPS and Revenue - GuruFocus
PAVmed Inc. SEC 10-Q Report - TradingView
Lucid Diagnostics Provides Business Update and Reports First Qua - GuruFocus
Lucid Diagnostics Reports Q1 2025 Financial Results - TipRanks
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results - StreetInsider
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - Finansavisen
Transcript : Lucid Diagnostics Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PAVmed (PAVM) to Release Quarterly Earnings on Thursday - Defense World
PAVmed to Hold a Business Update Conference Call and Webcast on - GuruFocus
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 - The Victoria Advocate
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 | PAVM Stock News - GuruFocus
PAVmed Sets Key Q1 2025 Earnings Call: MedTech Growth Strategy and Financial Results Coming May 15 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
PAVmed switches to new accounting firm post-acquisition - Investing.com Australia
PAVmed switches to new accounting firm post-acquisition By Investing.com - Investing.com South Africa
PAVmed, Lucid post encouraging results from EsoGuard study (LUCD:NASDAQ) - Seeking Alpha
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD - StreetInsider
Breakthrough: NCI Study Validates EsoGuard's Perfect Accuracy for Early Cancer Detection$60B Market Impact - Stock Titan
Ascendiant Capital Markets Forecasts Strong Price Appreciation for PAVmed (NASDAQ:PAVM) Stock - The AM Reporter
PAVmed (NASDAQ:PAVM) Price Target Raised to $19.50 at Ascendiant Capital Markets - Defense World
PAVmed Files Prospectus Relates To Potential Offer, Sale From Time To Time Of 3.3 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):